Efficacy Study of Recombinant Growth Hormone on Muscle Function in Children Long-term Treated With Glucocorticoid

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

May 31, 2012

Conditions
Chronic DiseaseGlucocorticoid Therapy, Response toGrowth Retardation
Interventions
DEVICE

GH treatment

GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.

Trial Locations (1)

75019

Hôpital Robert Debré, Paris

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Association REMEDE

OTHER